1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?

 
• By Brenda Sandburg

A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.

Two men change their common route taking different ways
FDA has previously parted ways with an advisory committee in approving a drug • Source: Shutterstock

The US Food and Drug Administration seemed ready to approve Biogen, Inc.’s Alzheimer’s disease drug aducanumab before an advisory committee voted that the sole positive Phase III study did not support the drug’s effectiveness. The question now is whether the agency will go through with approval or require Biogen to conduct an additional trial. A look back at other instances in which the FDA approved a drug against a panel’s recommendation shows aducanumab’s unique circumstances, which may deter the agency from pushing forward with approval.

Members of FDA’s Peripheral and Central Nervous System Drugs Advisory Committee sharply criticized the agency for its analysis of aducanumab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

August Brings Fresh Faces And Tough Calls To US FDA User Fee Calendar

 
• By Bridget Silverman

The FDA could act on 17 applications, including 10 novel agents, during August. Only one would be a second-cycle review.

Complete Response Letter Trio Raises Prospect Of Tidal Shift In Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 
• By Bridget Silverman

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year.

Slowdown: US FDA’s 2025 Novel Approvals Are On Below-Average Pace

 
• By Bridget Silverman

US FDA's 25 novel approvals in 2025 fell short of the agency's five-year average count, driven by a drop in drugs center approvals; 45 user fee goals remain in second half of year.

More from Regulatory Trackers